Rallybio (RLYB) Minority Interest (2020 - 2021)

Rallybio (RLYB) posted Minority Interest of $144.9 million for Q2 2021, little changed sequentially from $144.9 million in Q4 2020.

Rallybio (RLYB) Minority Interest (2020 - 2021) Analysis & Trends

Rallybio has reported Minority Interest for 2 years, with the latest figure at $144.9 million in Q2 2021.

Quarterly Minority Interest changed N/A year-over-year to $144.9 million in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $144.9 million (changed N/A YoY) and the FY2020 annual result came in at $144.9 million, changed N/A from the prior year.
Minority Interest steadied at $144.9 million in Q2 2021 per RLYB's latest filing, from $144.9 million in the prior quarter.
Over five years, Minority Interest peaked at $144.9 million in Q4 2020 and troughed at $144.9 million in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Rallybio	94.61 Mn	94.61 Mn	-

Download Data

Date	Value
Jun 30, 2021	144.89 Mn
Dec 31, 2020	144.89 Mn